Yale University

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

TitleSafety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Publication TypeJournal Article
Year of Publication2015
AuthorsGordon, Stuart C., Andrew J. Muir, Joseph K. Lim, Brian Pearlman, Curtis K. Argo, Ananthakrishnan Ramani, Benedict Maliakkal, Imtiaz Alam, Thomas G. Stewart, Monika Vainorius, Joy Peter, David R. Nelson, Michael W. Fried, and Rajender K. Reddy
Corporate AuthorsHCV-TARGET study group
JournalJournal of hepatology
Volume62
Issue2
Pagination286-93
Date Published2015 Feb
ISSN1600-0641
KeywordsAdolescent, Adult, Aged, Antiviral Agents, DNA, Viral, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Male, Middle Aged, Oligopeptides, Proline, Retrospective Studies, Treatment Outcome, Viral Load, Young Adult
AbstractThe safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated.
DOI10.1016/j.jhep.2014.08.052
Alternate JournalJ. Hepatol.

External Links